Evidence map›Paper›PMID 38965506›Full record

ArticleBMC cancer2024

Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1.

Cheng Yu, Yuanhui Su, Xin Miao, Changpeng Chai, Huan Tang, Lu Li, Jianfeng Yi, Zhenzhen Ye, Hui Zhang, Zhao Hu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Cheng Yu *The Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Yuanhui Su *The Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Xin Miao *The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, 310006, China.
Changpeng ChaiThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Huan TangThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Lu LiThe Fourth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, 730000, China.
Jianfeng YiThe First Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Zhenzhen YeThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Hui ZhangThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
Zhao HuThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310006, China.
Luyang ChenThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310006, China.
Ning LiThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310006, China. lining1963cool@163.com.
Hao XuThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310006, China. amoyxu@126.com.
Wence ZhouThe Second Clinical Medical School, Lanzhou University, Lanzhou, 730000, China. zhouwc129@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistance remains a significant challenge in the treatment of pancreatic cancer. The development of drug-resistant cell lines is crucial to understanding the underlying mechanisms of resistance and developing novel drugs to improve clinical outcomes. Here, a novel pancreatic cancer cell line, PDAC-X1, derived from Chinese patients has been established. PDAC-X1 was characterized by the immune phenotype, biology, genetics, molecular characteristics, and tumorigenicity. In vitro analysis revealed that PDAC-X1 cells exhibited epithelial morphology and cell markers (CK7 and CK19), expressed cancer-associated markers (E-cadherin, Vimentin, Ki-67, CEA, CA19-9), and produced pancreatic cancer-like organs in suspension culture. In vivo analysis showed that PDAC-X1 cells maintained tumorigenicity with a 100% tumor formation rate. This cell line exhibited a complex karyotype, dominated by subtriploid karyotypes. In addition, PDAC-X1 cells exhibited intrinsic multidrug resistance to multiple drugs, including gemcitabine, paclitaxel, 5-fluorouracil, and oxaliplatin. In conclusion, the PDAC-X1 cell line has been established and characterized, representing a useful and valuable preclinical model to study the underlying mechanisms of drug resistance and develop novel drug therapeutics to improve patient outcomes.

Indexed as

Carcinoma, Pancreatic DuctalDrug Resistance, MultipleDrug Resistance, NeoplasmPancreatic NeoplasmsAnimalsAntineoplastic AgentsBiomarkers, TumorCell Line, TumorDeoxycytidineFemaleGemcitabineHumansMaleMiceXenograft Model Antitumor AssaysAntineoplastic AgentsBiomarkers, TumorDeoxycytidineGemcitabineChemotherapyIntrinsic multidrug resistancePancreatic cancerTransplanted tumorTumor cell line

Identifiers

PMID38965506
PMCPMC11225239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.